

08-09-02

1631

Express Mail No.: EL 451 598 014 US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Usuka *et al.*

Confirmation No.: 3878

Serial No.: 10/015,167

Group Art Unit: 2376

Filed: December 11, 2001

Examiner: Not yet assigned

For: SYSTEM AND METHOD FOR  
PREDICTING CHROMOSOMAL  
REGIONS THAT CONTROL  
PHENOTYPIC TRAITS

Attorney Docket No.: 9080-016-999

#6  
Plunkett  
8/13/02

## INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

AUG 13 2002

TECH CENTER 1600/2900

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

## 1. Enclosures accompanying this Information Disclosure Statement are:

- 1a.  A list of all patents, publications, applications, or other information submitted for consideration by the office.
- 1b. A legible copy of:
  - Each U.S. patent application publication and U.S. and foreign patent;
  - Each publication or that portion which caused it to be listed on the PTO-1449 (AX-AY);
  - For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;
  - all other information or portion which caused it to be listed on the PTO-1449.
- 1c.  An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.

1d.  Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.

2.  This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):  
 Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);  
 Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;  
 Before the mailing of the first Office action on the merits;  
 Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.

3.  This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.

*(Check either Item 3a or 3b)*

3a.  The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.

3b.  The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:  
 enclosed  
 to be charged to Pennie & Edmonds LLP Deposit Account No. 16-1150.

*(Item 3b to be checked if any reference known for more than 3 months)*

4.  This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.

The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:

enclosed.  
 to be charged to Pennie & Edmonds LLP Deposit Account No. 16-1150.

The Certification Statement in Item 5 below is applicable.

5.  Certification Statement *(applicable if Item 3a or Item 4 is checked)*

*(Check either Item 5a or 5b)*

5a.  In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

5b.  In accordance with 37 C.F.R. §1.97(e)(2), it is certified that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was known by any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

6.  This application is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).

*(Check appropriate Items 6a, 6b and/or 6c)*

6a.  A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.

6b.  Copies of publications listed on Form PTO-1449 (AW, and AZ-BJ) from prior application Serial No. 09/737,918, filed on December 15, 2000, of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).

6c.  Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. , filed on , and are provided herewith.

7.  This is a Supplemental Information Disclosure Statement. *(Check either Item 7a or 7b)*

7a.  This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on \_\_\_. A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on \_\_\_.

7b.  This Supplemental Information Disclosure Statement is timely filed within one (1) month of a PTO Notice under 37 C.F.R. §1.97(i).

8.  In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:

*(Check Item 8a, 8b, or 8c)*

8a.  satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.

8b.  set forth in the application.

8c.  enclosed as an attachment hereto.

9.  The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Pennie & Edmonds LLP Deposit Account No. 16-1150.

10.  No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).


Date August 7, 2002

Respectfully submitted,

*Bretly Sorey Reg. No. 42,813*

Francis E. Morris  
PENNIE & EDMONDS LLP  
1155 Avenue of Americas  
New York NY 10036-2720  
(212) 790 - 9090

24,615  
(Reg. No.)



## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 9080-016-999	APPLICATION NO. 10/015,167
APPLICANT	
Usuka et al.	
FILING DATE December 11, 2001	GROUP 2376

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AW	6,291,182 B1	09/18/01	Schork et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	AX	International Search Report From PCT/US01/48524	07/25/02	PCT			YES NO

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

AY	Buetow et al., 1991, "A detailed multipoint map of human chromosome 4 provides evidence for linkage heterogeneity and position-specific recombination rates," <i>Am. J. Hum. Genet.</i> 48:911-925
AZ	Alison et al., 1998 "Multiple phenotype modeling in gene-mapping studies of quantitative traits: power advantages," <i>Am. J. Hum. Genet.</i> 63:1190-1201
BA	Amos et al., 1990 "A multivariate method for detecting genetic linkage, with application to a pedigree with an adverse lipoprotein phenotype," <i>Am. J. Hum. Genet.</i> 47:247-254
BB	Eisen et al., 1998 "Cluster analysis and display of genome-wide expression patterns," <i>Proc. Natl. Acad. Sci USA</i> 95:14863-14868
BC	Golub et al., 1999 "Molecular classification of cancer: class discovery and class prediction by gene expression monitoring," <i>Science</i> 286:531-537
BD	Machleder et al., 1997 "Complex genetic control of HDL levels in mice in response to an atherogenic diet," <i>J. Clin. Invest.</i> 99:1406-1419
BE	Olson et al., 1999 "Tutorial in biostatistics genetic mapping of complex traits," <i>Statist. Med.</i> 18:2961-2981
BF	Schadt et al., 1998 "Computational Advances in maximum likelihood methods for molecular phylogeny," <i>Genome Research</i> 8:222-233
BG	Schaid et al., 1994 "Comparison of statistics for candidate-gene associate studies using cases and parents," <i>Am. J. Hum. Genet.</i> 55: 402-409
BH	Schork et al., 1998 "The future of genetic epidemiology," <i>TIG</i> 14: 266-272
BI	Weeks et al., 1995 "Polygenic disease: methods for mapping complex disease traits," <i>TIG</i> 11:513-516
BJ	Risch, 2000, "Searching for genetic determinants in the new millennium," <i>Nature</i> 405:847-856

EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO 9080-016-999	APPLICATION NO 10/015,167
				APPLICANT Usuka et al.	
				FILING DATE December 11, 2001	GROUP 2376

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AW	6,291,182 B1	09/18/01	Schork et al.			

## FOREIGN PATENT DOCUMENTS

	AX	DOCUMENT NUMBER International Search Report From PCT/US01/48524	DATE 07/25/02	COUNTRY PCT	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

AY	Buetow et al., 1991, "A detailed multipoint map of human chromosome 4 provides evidence for linkage heterogeneity and position-specific recombination rates," <i>Am. J. Hum. Genet.</i> 48:911-925
AZ	Alison et al., 1998 "Multiple phenotype modeling in gene-mapping studies of quantitative traits: power advantages," <i>Am. J. Hum. Genet.</i> 63:1190-1201
BA	Amos et al., 1990 "A multivariate method for detecting genetic linkage, with application to a pedigree with an adverse lipoprotein phenotype," <i>Am. J. Hum. Genet.</i> 47:247-254
BB	Eisen et al., 1998 "Cluster analysis and display of genome-wide expression patterns," <i>Proc. Natl. Acad. Sci USA</i> 95:14863-14868
BC	Golub et al., 1999 "Molecular classification of cancer: class discovery and class prediction by gene expression monitoring," <i>Science</i> 286:531-537
BD	Machleider et al., 1997 "Complex genetic control of HDL levels in mice in response to an atherogenic diet," <i>J. Clin. Invest.</i> 99:1406-1419
BE	Olson et al., 1999 "Tutorial in biostatistics genetic mapping of complex traits," <i>Statist. Med.</i> 18:2961-2981
BF	Schadt et al., 1998 "Computational Advances in maximum likelihood methods for molecular phylogeny," <i>Genome Research</i> 8:222-233
BG	Schaid et al., 1994 "Comparison of statistics for candidate-gene associate studies using cases and parents," <i>Am. J. Hum. Genet.</i> 55: 402-409
BH	Schork et al., 1998 "The future of genetic epidemiology," <i>TIG</i> 14: 266-272
BI	Weeks et al., 1995 "Polygenic disease: methods for mapping complex disease traits," <i>TIG</i> 11:513-516
BJ	Risch, 2000, "Searching for genetic determinants in the new millennium," <i>Nature</i> 405:847-856

EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

AUG 13 2002

TECH CENTER 1600  
MAIL CODE 1600  
USPTO

CA1 - 313284.1